Real-time Stock quotes, portfolio, LIVE TV and more.
Jan 01, 1970, 05.29 AM IST
Preliminary data from second pivotal Phase III study showed Lucentis® maintained or improved vision in 95 percent of patients with age-related macular degeneration (AMD).
Tags: Preliminary data, pivotal Phase III study, Lucentis, AMD, PDT, Lucentis , MARINA , Lucentis , Visudyne, ANti-VEGF, ETDRS
May 23 2013, 16:33
- in Asian markets
May 23 2013, 09:33
- in Technicals